Triptorelin acetate administration in early pregnancy: case reports and review of the literature.
When using a long protocol with cycle day 23 gonadotrophin-releasing hormone agonists (GnRH-a) administration, an elevated estradiol level or a missed period 10-14 days after initiating pituitary downregulation should alert the physician to the possibility of a pregnancy. We report 4 pregnancies occurring during pituitary downregulation with Triptorelin acetate in 366 in-vitro fertilization (IVF) cycles resulting in 3 deliveries of 4 normal neonates at term and 1 first trimester abortion. This supports published data reporting a 1% spontaneous pregnancy incidence in women undergoing pituitary desensitization GnRH-a during the luteal phase prior to planned IVF treatment, a 15.9% abortion rate and a 1.7% malformation rate. Our cases together with other published data suggest that pregnancy outcome is not adversely affected by GnRH-a administration during the luteal phase of the conception cycle. However, long term follow-up of these babies is still lacking and the number of reported cases is too small adequately to rule out the possibility of any detrimental effect related GnRH-a administration in pregnancy.
Chardonnens
D
D
Department of Obstetrics and Gynecology, Clinic of Infertility and Gynecological Endocrinology, WHO Collaborating Center in Human Reproduction, University Hospital of Geneva, Switzerland. chardonnens-didier@diogenes.hcuge.ch
Sylvan
K
K
Walker
D
D
Bischof
P
P
Sakkas
D
D
Campana
A
A
D000022:Abortion, Spontaneous; D000328:Adult; D005260:Female; D005307:Fertilization in Vitro; D005865:Gestational Age; D006801:Humans; D008297:Male; D011247:Pregnancy; D011256:Pregnancy Outcome; D017329:Triptorelin Pamoate / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
D017329:Triptorelin Pamoate